A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms RELEVANCE
- Sponsors Celgene Corporation
- 31 Oct 2017 Planned primary completion date changed from 1 May 2017 to 1 Jun 2024.
- 27 Jul 2017 According to a Celgene Corporation media release, data from this study is expected in the second half of 2017.
- 28 Dec 2016 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017.